Search results
Showing 61 to 75 of 169 results for asthma
In development Reference number: GID-TA11246 Expected publication date: 11 February 2026
of FeNO measurement in asthma management. It accepted that currently available evidence on the use of FeNO measurement in...
Recommendation ID NG80/5 Question Monitoring asthma control using tele-healthcare:- What is the long-term (more than 12 months) clinical
beta2 agonist (LABA) in the treatment of asthma in children and young people (under 16) who have uncontrolled asthma on a...
pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and...
This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Smoking: smoking status for people with long-term conditions (IND97)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38
In development Reference number: GID-HTE10065 Expected publication date: 02 April 2026
need to further establish the accuracy of current practice in diagnosing asthma and the incremental accuracy associated with the...
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
This quality standard covers diagnosing, assessing and treating community-acquired and hospital-acquired pneumonia in babies over 1 month (corrected gestational age), children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover ventilator associated pneumonia or COVID-19 pneumonia.
View quality statements for QS110Show all sections
Sections for QS110